May 2, 2018 / 10:08 AM / 3 months ago

BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14

May 2 (Reuters) - Acorda Therapeutics Inc:

* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018

* Q1 NON-GAAP EARNINGS PER SHARE $0.14

* Q1 REVENUE $103 MILLION

* Q1 EARNINGS PER SHARE VIEW $0.47 — THOMSON REUTERS I/B/E/S

* Q1 REVENUE VIEW $129.9 MILLION — THOMSON REUTERS I/B/E/S

* EXPECTS TO END 2018 WITH A PROJECTED YEAR-END CASH BALANCE IN EXCESS OF $300 MILLION

* FDA ACCEPTED INBRIJA(LEVODOPA INHALATION POWDER) NDA; PDUFA DATE OCTOBER 5, 2018

* ACORDA THERAPEUTICS SAYS EXPECTS TO MAINTAIN EXCLUSIVITY OF AMPYRA AT LEAST THROUGH JULY 30, 2018

* ACORDA THERAPEUTICS - 2018 RESEARCH AND DEVELOPMENT EXPENSES EXPECTED TO BE $100 MILLION TO $110 MILLION AND INCLUDE MANUFACTURING EXPENSES ASSOCIATED WITH INBRIJA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below